var data={"title":"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/contributors\" class=\"contributor contributor_credentials\">Kristin M Leiferman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/contributors\" class=\"contributor contributor_credentials\">John J Zone, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 07, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H590249\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bullous pemphigoid and mucous membrane pemphigoid (MMP) are autoimmune blistering diseases that most commonly arise in older adults. These disorders are characterized by subepithelial blister formation and the deposition of immunoglobulins and complement within the epidermal <span class=\"nowrap\">and/or</span> mucosal basement membrane zone.</p><p>Although both bullous pemphigoid and MMP may affect skin and mucosa, the classical clinical findings in bullous pemphigoid are tense, fluid-filled bullae on skin whereas the prevailing clinical feature in MMP is mucosal involvement. In MMP, inflamed and eroded mucosa is characteristic, involving any or all of the oral cavity, ocular conjunctiva, nose, pharynx, larynx, esophagus, anus, and genital mucous membranes.</p><p>The clinical features and diagnosis of bullous pemphigoid and MMP will be reviewed here. The epidemiology, pathogenesis, and treatment of these disorders as well as greater detail on the ocular form of MMP (ocular cicatricial pemphigoid) and other autoimmune blistering disorders are discussed separately. (See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid&quot;</a> and <a href=\"topic.htm?path=management-and-prognosis-of-bullous-pemphigoid\" class=\"medical medical_review\">&quot;Management and prognosis of bullous pemphigoid&quot;</a> and <a href=\"topic.htm?path=management-of-mucous-membrane-pemphigoid\" class=\"medical medical_review\">&quot;Management of mucous membrane pemphigoid&quot;</a> and <a href=\"topic.htm?path=ocular-cicatricial-pemphigoid\" class=\"medical medical_review\">&quot;Ocular cicatricial pemphigoid&quot;</a> and <a href=\"topic.htm?path=dermatoses-of-pregnancy#H2\" class=\"medical medical_review\">&quot;Dermatoses of pregnancy&quot;, section on 'Pemphigoid gestationis'</a> and <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H784094\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H53290498\"><span class=\"h2\">Bullous pemphigoid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A prodromal phase lasting weeks to months may precede the development of cutaneous bullae in patients with bullous pemphigoid [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The prodromal phase may present with pruritic eczematous, papular, or urticaria-like skin lesions (<a href=\"image.htm?imageKey=DERM%2F80385\" class=\"graphic graphic_picture graphicRef80385 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/3\" class=\"abstract_t\">3</a>]. Some patients with bullous pemphigoid never develop blistering.</p><p>When blisters develop, the classical lesion is a 1 to 3 cm tense bulla on an erythematous, urticarial, or noninflammatory base, and blisters may be numerous and widespread (<a href=\"image.htm?imageKey=DERM%2F54541%7EDERM%2F70352%7EDERM%2F79112\" class=\"graphic graphic_picture graphicRef54541 graphicRef70352 graphicRef79112 \">picture 2A-C</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/4\" class=\"abstract_t\">4</a>]. Associated pruritus is common and can be severe [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/5,6\" class=\"abstract_t\">5,6</a>]. The tense quality of the bullae differentiates the lesions of bullous pemphigoid from the flaccid bullae of pemphigus vulgaris (<a href=\"image.htm?imageKey=DERM%2F53425\" class=\"graphic graphic_picture graphicRef53425 \">picture 3A</a>) (see <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/2,7\" class=\"abstract_t\">2,7</a>]. Eventually, the bullae rupture, leaving moist erosions and crusts that resolve without scarring. When mainly erosions are present, it may be difficult to clinically distinguish bullous pemphigoid and pemphigus (<a href=\"image.htm?imageKey=DERM%2F63170\" class=\"graphic graphic_picture graphicRef63170 \">picture 3B</a>). </p><p>The trunk, extremity flexures, and axillary and inguinal folds are common sites for cutaneous involvement (<a href=\"image.htm?imageKey=DERM%2F72866%7EDERM%2F78910%7EDERM%2F59590\" class=\"graphic graphic_picture graphicRef72866 graphicRef78910 graphicRef59590 \">picture 4A-C</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/8\" class=\"abstract_t\">8</a>]. Mucosal lesions, which typically are erosions of the oral mucosa, are present in 10 to 30 percent of patients (<a href=\"image.htm?imageKey=DERM%2F66179\" class=\"graphic graphic_picture graphicRef66179 \">picture 5</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/1,2,4\" class=\"abstract_t\">1,2,4</a>]. Nail changes also may develop [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/9,10\" class=\"abstract_t\">9,10</a>].</p><p>Localized forms of bullous pemphigoid also occur, and account for up to 30 percent of cases [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/11\" class=\"abstract_t\">11</a>]. Examples include disease limited to the lower legs (<a href=\"image.htm?imageKey=DERM%2F71249\" class=\"graphic graphic_picture graphicRef71249 \">picture 6</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/11-15\" class=\"abstract_t\">11-15</a>], anogenital region [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/16,17\" class=\"abstract_t\">16,17</a>], peristomal skin [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/18,19\" class=\"abstract_t\">18,19</a>], or sites of incidental or iatrogenic trauma (eg, radiation therapy) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/20-26\" class=\"abstract_t\">20-26</a>]. Disease that begins in localized areas may remain localized or may progress to generalized involvement [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/11,27\" class=\"abstract_t\">11,27</a>]. </p><p>Other reported clinical variants of bullous pemphigoid include eczematous, urticarial, and prurigo-like (pemphigoid nodularis) presentations, as well as bullous pemphigoid presenting as pruritus without any primary skin lesions (pruritic nonbullous pemphigoid, bullous pemphigoid as pruritus in older adults); in such cases, the diagnosis is based upon consistent laboratory findings (see <a href=\"#H20007014\" class=\"local\">'Laboratory tests'</a> below) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/1,28-30\" class=\"abstract_t\">1,28-30</a>]. Rare variants include pemphigoid vegetans, which manifests with verruciform plaques in intertriginous areas [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/31,32\" class=\"abstract_t\">31,32</a>], dyshidrosiform pemphigoid, which occurs on palmar <span class=\"nowrap\">and/or</span> plantar skin (resembling dyshidrotic eczema) and often is hemorrhagic (<a href=\"image.htm?imageKey=DERM%2F50357\" class=\"graphic graphic_picture graphicRef50357 \">picture 7</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/33,34\" class=\"abstract_t\">33,34</a>], and vesicular bullous pemphigoid, in which lesions resemble dermatitis herpetiformis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/35\" class=\"abstract_t\">35</a>].</p><p>Lichen planus pemphigoides is another rare variant of bullous pemphigoid. It is postulated that the cellular inflammatory process that occurs at the basement membrane zone in lichen planus results in exposure of basement membrane zone antigens leading to subsequent development of basement membrane zone antibodies [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/36\" class=\"abstract_t\">36</a>]. Patients with lichen planus pemphigoides typically present with bullae in sites of previously normal-appearing skin or mucosa. The bullae usually appear weeks to months after the onset of lichen planus [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H53290512\"><span class=\"h2\">Mucous membrane pemphigoid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MMP represents a group of heterogeneous, chronic subepithelial blistering disorders that primarily affect mucosal surfaces [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/37\" class=\"abstract_t\">37</a>]. Historically, the term cicatricial pemphigoid also referred to these disorders. Some authors also consider cases of linear IgA bullous dermatosis and epidermolysis bullosa acquisita that primarily involve the mucous membranes as forms of MMP [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/37\" class=\"abstract_t\">37</a>]. However, our approach is to view these diagnoses as distinct entities. (See <a href=\"topic.htm?path=linear-iga-bullous-dermatosis\" class=\"medical medical_review\">&quot;Linear IgA bullous dermatosis&quot;</a> and <a href=\"topic.htm?path=epidermolysis-bullosa-acquisita\" class=\"medical medical_review\">&quot;Epidermolysis bullosa acquisita&quot;</a>.)</p><p>MMP typically presents as relapsing and remitting mucosal inflammation and erosions (<a href=\"image.htm?imageKey=DERM%2F73874%7EDERM%2F52208%7EDERM%2F63997\" class=\"graphic graphic_picture graphicRef73874 graphicRef52208 graphicRef63997 \">picture 8A-C</a>). The oral cavity is the most common site of involvement, and cutaneous involvement also may be present. In a report that summarized the sites of involvement in 457 patients with MMP, the frequency of affected sites was as follows [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/38\" class=\"abstract_t\">38</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oral mucosa (85 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ocular conjunctiva (64 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Skin (24 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pharynx (19 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>External genitalia (17 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nasal mucosa (15 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Larynx (8 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anus (4 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Esophagus (4 percent)</p><p/><p>In the oral cavity, the gingival and buccal mucosae are most commonly affected. Gingival disease usually manifests as a desquamative or erosive gingivitis (<a href=\"image.htm?imageKey=DERM%2F73874\" class=\"graphic graphic_picture graphicRef73874 \">picture 8A</a>), and, in mild cases, may manifest only with gingival erythema and edema [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/39\" class=\"abstract_t\">39</a>]. The detection of intact vesicles or bullae on mucosa is uncommon. Compared with the mucosal lesions of pemphigus, pain associated with oral MMP lesions is usually less intense [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Scarring is a common consequence of MMP that distinguishes this variant from mucosal involvement in bullous pemphigoid, which typically does not scar. Reticulated, white striations representing mucosal fibrosis often are present at sites of healed lesions, and functional limitations secondary to scarring may occur [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/1,39\" class=\"abstract_t\">1,39</a>]. As examples, MMP involving the ocular mucosa can lead to symblepharon, ankyloblepharon, and eventual blindness, and progressive laryngeal and tracheal involvement can result in asphyxiation [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/39\" class=\"abstract_t\">39</a>]. (See <a href=\"topic.htm?path=ocular-cicatricial-pemphigoid#H2913497\" class=\"medical medical_review\">&quot;Ocular cicatricial pemphigoid&quot;, section on 'Clinical manifestations'</a>.)</p><p>Cutaneous involvement in patients with MMP typically involves the scalp, face, or upper trunk. The bullous lesions resemble those seen in bullous pemphigoid, but, similar to mucosal lesions of MMP, often heal with scarring.</p><p class=\"headingAnchor\" id=\"H3867557\"><span class=\"h1\">ASSOCIATED DISORDERS</span></p><p class=\"headingAnchor\" id=\"H3867564\"><span class=\"h2\">Neurologic disorders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Associations between bullous pemphigoid and neurologic disorders have been reported in several observational studies and case reports [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/40-51\" class=\"abstract_t\">40-51</a>]. In a hospital-based prospective case-control study of 201 patients with bullous pemphigoid and 345 matched controls, dementia, Parkinson's disease, and unipolar or bipolar disorder were among the identified independent risk factors for this disease [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/43\" class=\"abstract_t\">43</a>]. In addition, a population-based case-control study of 868 patients with bullous pemphigoid and more than 3400 controls found that patients with preexisting diagnoses of dementia, Parkinson's disease, or stroke were significantly more likely to develop bullous pemphigoid [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/42\" class=\"abstract_t\">42</a>]. Further, a case-control study with more than 5000 patients with multiple sclerosis and over 26,000 controls supported an association of bullous pemphigoid and this disease [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/52\" class=\"abstract_t\">52</a>]. </p><p>Homology between bullous pemphigoid antigens in the skin and neuronal antigens in the central nervous system has been proposed as a cause for the observed link between bullous pemphigoid and neurologic disease [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/53-56\" class=\"abstract_t\">53-56</a>]. However, further studies are necessary to explore the relationship between these disorders. (See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid#H590428\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid&quot;, section on 'Epitope spreading'</a>.)</p><p class=\"headingAnchor\" id=\"H3867571\"><span class=\"h2\">Malignancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MMP with antibodies directed against laminin 332 (previously known as laminin 5 and epiligrin) has been associated with an increased risk for internal malignancy (<a href=\"image.htm?imageKey=DERM%2F67891\" class=\"graphic graphic_figure graphicRef67891 \">figure 1</a>). In a cohort of 35 patients with this type of MMP (diagnosed with immunoprecipitation), 10 (29 percent) developed solid organ malignancies, 7 of which were diagnosed within 14 months after a diagnosis of MMP [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/57\" class=\"abstract_t\">57</a>]. Occurrences of non-Hodgkin lymphoma and cutaneous T cell lymphoma have also been reported in individual patients with anti-laminin 332 MMP [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/58\" class=\"abstract_t\">58</a>]. The pathophysiological relationship of this subtype of MMP to cancer is unknown. However, expression of laminin 332 has been detected in malignant cells, and laminin 332 appears to be capable of promoting tumor cell growth, invasion, and metastasis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/58,59\" class=\"abstract_t\">58,59</a>].</p><p>The clinical manifestations of MMP in patients with laminin 332 antibodies are similar to the features of MMP with other antibody profiles. Therefore, clinical examination cannot reliably distinguish anti-laminin 332 MMP from other forms of MMP. Additional studies are necessary to confirm the findings of a retrospective study of 154 patients with MMP that associated the detection of laminin 332 antibodies via a novel ELISA assay with a greater likelihood for severe disease [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/60\" class=\"abstract_t\">60</a>].</p><p>Since diagnostic laboratory testing for laminin 332 antibodies is not commercially available, suspicion for laminin 332 primarily is based upon immunofluorescence microscopy findings. Although not exclusive to laminin 332 MMP, the detection of antibodies bound to the dermal side of basement membrane zone-split (salt-split) skin suggests the possibility of this diagnosis. (See <a href=\"#H53290540\" class=\"local\">'Indirect immunofluorescence of serum'</a> below.)</p><p>Until definitive testing for laminin 332 antibodies becomes available, we recommend that patients with MMP in whom serum indirect immunofluorescence (IIF) studies reveal antibodies bound to the dermal side of basement membrane zone-split skin undergo age and gender appropriate cancer screening. Additional evaluation for malignancy should be performed as indicated based upon a review of symptoms, physical examination, and the results of age-appropriate screening. </p><p>The relationship between bullous pemphigoid and malignancy is less clear. While some studies support an association, others have failed to find a significant increase in malignancy risk, attributing occurrences of malignancy to age rather than bullous pemphigoid [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/61,62\" class=\"abstract_t\">61,62</a>]. Further study is necessary to confirm the findings of individual studies that have found a disproportionate increase in risk for malignancy in young versus old individuals with bullous pemphigoid [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/61\" class=\"abstract_t\">61</a>] and increased risk for bullous pemphigoid limited to individuals with specific forms of cancer (renal cancer, laryngeal cancer, and lymphoid leukemia) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/63\" class=\"abstract_t\">63</a>]. As a precaution, we evaluate young and middle-aged patients with bullous pemphigoid for underlying malignancy, particularly when they present with severe or refractory disease.</p><p class=\"headingAnchor\" id=\"H785112\"><span class=\"h1\">DISEASE COURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bullous pemphigoid is a chronic disorder characterized by exacerbations and remissions over the course of months to years. However, in some patients the disease is self-limited, resulting in disease remissions within a few years. (See <a href=\"topic.htm?path=management-and-prognosis-of-bullous-pemphigoid#H24368306\" class=\"medical medical_review\">&quot;Management and prognosis of bullous pemphigoid&quot;, section on 'Prognosis'</a>.)</p><p>In the absence of treatment, MMP is usually a chronic, progressive disease that results in functionally limiting or, in some cases (such as those with airway involvement), life-threatening disease [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/39\" class=\"abstract_t\">39</a>]. The clinical course and prognosis of ocular MMP is reviewed in greater detail separately. (See <a href=\"topic.htm?path=ocular-cicatricial-pemphigoid#H2913497\" class=\"medical medical_review\">&quot;Ocular cicatricial pemphigoid&quot;, section on 'Clinical manifestations'</a> and <a href=\"topic.htm?path=ocular-cicatricial-pemphigoid#H2913561\" class=\"medical medical_review\">&quot;Ocular cicatricial pemphigoid&quot;, section on 'Prognosis and cessation of therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H20007006\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although clinical findings may strongly suggest bullous pemphigoid or MMP, other disorders present with similar mucocutaneous lesions, and atypical presentations can occur (<a href=\"image.htm?imageKey=DERM%2F69192\" class=\"graphic graphic_table graphicRef69192 \">table 1</a>) (see <a href=\"#H20007021\" class=\"local\">'Differential diagnosis'</a> below). Thus, confirmation of the diagnosis requires the careful interpretation of both clinical and laboratory findings.</p><p class=\"headingAnchor\" id=\"H587825\"><span class=\"h2\">Clinical assessment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical features that suggest bullous pemphigoid or MMP in patients over the age of 60 years include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blistering skin disease characterized by the presence of tense blisters and erosions that occur without another identifiable cause</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Desquamative gingivitis or mucositis involving oral, ocular, nasal, genital, anal, pharyngeal, laryngeal, <span class=\"nowrap\">and/or</span> esophageal mucosae</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unexplained pruritic eczematous eruptions or urticarial plaques</p><p/><p>The possibility of bullous pemphigoid or MMP also should be considered in the evaluation of younger individuals (including children) with suggestive symptoms in the absence of another identifiable cause (<a href=\"image.htm?imageKey=DERM%2F58359\" class=\"graphic graphic_picture graphicRef58359 \">picture 9</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/64,65\" class=\"abstract_t\">64,65</a>]. In patients with signs or symptoms of these disorders, laboratory assessment is indicated. (See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid#H589244\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid&quot;, section on 'Epidemiology'</a>.)</p><p class=\"headingAnchor\" id=\"H20007014\"><span class=\"h2\">Laboratory tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The principal studies used in the evaluation of patients with lesions suspicious for bullous pemphigoid or MMP include (<a href=\"image.htm?imageKey=DERM%2F57402\" class=\"graphic graphic_table graphicRef57402 \">table 2</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A<strong> lesional</strong> skin biopsy from<strong> </strong>the edge of<strong> </strong>an intact blister (or other <span class=\"nowrap\">inflamed/affected</span> tissue, urticarial or eczematous) for hematoxylin and eosin (H&amp;E) staining and a skin biopsy from <strong>perilesional</strong> tissue for direct immunofluorescence (DIF). DIF is considered <strong>the gold standard</strong> for diagnosis. (See <a href=\"#H554282\" class=\"local\">'Skin biopsy'</a> below and <a href=\"topic.htm?path=approach-to-the-patient-with-cutaneous-blisters#H4714350\" class=\"medical medical_review\">&quot;Approach to the patient with cutaneous blisters&quot;, section on 'Skin biopsy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A serum specimen for indirect immunofluorescence (IIF) and enzyme linked immunosorbent assay (ELISA) testing to detect circulating basement membrane zone antibodies. (See <a href=\"topic.htm?path=approach-to-the-patient-with-cutaneous-blisters#H320553\" class=\"medical medical_review\">&quot;Approach to the patient with cutaneous blisters&quot;, section on 'Serologic tests'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H404213\"><span class=\"h3\">Our approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with clinical findings suggestive of bullous pemphigoid or MMP, we begin the laboratory assessment by obtaining both a <strong>lesional</strong> tissue specimen for routine (fixed tissue) histopathology and a <strong>perilesional</strong> tissue specimen for DIF examinations. Bullous pemphigoid antigens may be sparse in distal anatomical locations; therefore, when possible, choosing a proximal anatomical site for the perilesional DIF specimen is preferred. Obtaining a lesional specimen often is difficult in MMP involving the mouth and vulva, because affected mucosa is friable and easily erodes. When this occurs, perilesional tissue should still be obtained for DIF.</p><p>Serologic studies provide additional information that is useful for diagnosis and patient management in most patients. IIF performed on basement membrane zone-split skin substrate aids in distinguishing bullous pemphigoid from epidermolysis bullosa acquisita and can identify patients with MMP who are at risk for malignancy-associated laminin 332 (epiligrin) MMP. Because of its value, we perform IIF in all patients with histopathologic <span class=\"nowrap\">and/or</span> DIF findings consistent with bullous pemphigoid or MMP. (See <a href=\"#H3867571\" class=\"local\">'Malignancy'</a> above and <a href=\"#H53290540\" class=\"local\">'Indirect immunofluorescence of serum'</a> below and <a href=\"topic.htm?path=epidermolysis-bullosa-acquisita#H316627112\" class=\"medical medical_review\">&quot;Epidermolysis bullosa acquisita&quot;, section on 'Diagnosis'</a>.)</p><p>In addition, serologic studies can be of value when DIF is negative in a patient with clinical and histopathologic findings that are consistent with bullous pemphigoid or when it is not possible to obtain adequate biopsy tissue [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/66\" class=\"abstract_t\">66</a>]. The combination of IIF and ELISA serum testing is useful to support a clinical diagnosis of bullous pemphigoid [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/67\" class=\"abstract_t\">67</a>]. </p><p>An algorithm depicting our approach to the diagnosis of patients who present with skin lesions suspicious for bullous pemphigoid and oral lesions suggestive of MMP is provided (<a href=\"image.htm?imageKey=DERM%2F76558\" class=\"graphic graphic_algorithm graphicRef76558 \">algorithm 1</a>).</p><p class=\"headingAnchor\" id=\"H554282\"><span class=\"h3\">Skin biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Separate specimens are optimal for H&amp;E (light microscopy of fixed tissue) and DIF because of differences in the requirements for the preferred biopsy location and tissue handling. We typically obtain two 4 mm punch biopsies. However, careful splitting of a 5 or 6 mm punch biopsy specimen or a shave biopsy specimen into lesional and perilesional specimens is an additional option. If only one small specimen can be obtained, the preferred test to perform is DIF. (See <a href=\"topic.htm?path=skin-biopsy-techniques#H12\" class=\"medical medical_review\">&quot;Skin biopsy techniques&quot;, section on 'Punch biopsy'</a> and <a href=\"topic.htm?path=approach-to-the-patient-with-cutaneous-blisters#H4714350\" class=\"medical medical_review\">&quot;Approach to the patient with cutaneous blisters&quot;, section on 'Skin biopsy'</a>.)</p><p class=\"headingAnchor\" id=\"H4988524\"><span class=\"h4\">Light microscopy of formalin-fixed tissue</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Biopsies for H&amp;E staining should be taken from lesional skin, preferably from an intact vesicle or the edge of an intact bulla (<a href=\"image.htm?imageKey=DERM%2F57402\" class=\"graphic graphic_table graphicRef57402 \">table 2</a>). The specimen should include the blister edge and the immediately adjacent tissue. Care should be taken to avoid excessive torsion and crushing, which may alter tissue cleavage planes and increase the difficulty of pathologic interpretation. Specimens obtained for H&amp;E are placed in formalin for processing.</p><p>Common histopathologic findings in cutaneous lesions of bullous pemphigoid include [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eosinophilic spongiosis (particularly in early lesions) (<a href=\"image.htm?imageKey=DERM%2F79687\" class=\"graphic graphic_picture graphicRef79687 \">picture 10</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Subepidermal blister formation (often with numerous eosinophils within cleft) (<a href=\"image.htm?imageKey=PC%2F66267\" class=\"graphic graphic_picture graphicRef66267 \">picture 11</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A superficial dermal inflammatory cell infiltrate of variable intensity with lymphocytes, eosinophils, and neutrophils (<a href=\"image.htm?imageKey=PC%2F66267\" class=\"graphic graphic_picture graphicRef66267 \">picture 11</a>)</p><p/><p>Histopathologic examination of mucosal lesions of MMP shows epithelial-subepithelial cleavage and a mixed submucosal inflammatory cell infiltrate composed of lymphocytes, histiocytes, neutrophils, and eosinophils [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/39\" class=\"abstract_t\">39</a>]. Additional findings may include plasma cell infiltration and subepidermal fibrosis; the latter is a finding consistent with the scarring nature of MMP [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/39\" class=\"abstract_t\">39</a>].</p><p class=\"headingAnchor\" id=\"H53290533\"><span class=\"h4\">Direct immunofluorescence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Direct immunofluorescence (DIF) studies are considered the gold standard for the diagnosis of pemphigoid [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/66,68\" class=\"abstract_t\">66,68</a>]. The procedure utilizes labeled antibodies to detect immunoglobulin binding and complement deposits in tissue. DIF is a more sensitive test for the diagnosis of bullous pemphigoid than IIF or ELISA tests [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/66\" class=\"abstract_t\">66</a>]. (See <a href=\"topic.htm?path=approach-to-the-patient-with-cutaneous-blisters#H4714358\" class=\"medical medical_review\">&quot;Approach to the patient with cutaneous blisters&quot;, section on 'Direct immunofluorescence'</a>.)</p><p>In contrast to biopsy specimens for H&amp;E histopathologic evaluation, biopsy specimens for DIF should be obtained from <strong>perilesional</strong>, not lesional skin (<a href=\"image.htm?imageKey=DERM%2F57402\" class=\"graphic graphic_table graphicRef57402 \">table 2</a>). For affected skin, this can be an erythematous or urticarial area adjacent to a blister. For affected mucosa, in which tissue immediately adjacent to an erosion can be friable, a tissue specimen from normal-appearing mucosa several millimeters away from the edge of a lesion can be obtained. </p><p>The tissue specimen for DIF <strong>should NOT be placed in formalin</strong>, rather a tissue transport medium compatible with the performance of immunofluorescence studies such as Michel's medium or Zeus medium should be used for specimen transport. Specimens for DIF should be transported promptly to an immunodermatology laboratory for receipt within seven days of obtaining the specimen; transport medium does not preserve a specimen indefinitely. Some immunodermatology laboratories also will accept specimens transported on normal saline soaked gauze (provided they are received during laboratory working hours within six hours of obtaining them; sooner is better) or specimens that are flash-frozen with liquid nitrogen and transported on dry ice (<a href=\"image.htm?imageKey=DERM%2F57402\" class=\"graphic graphic_table graphicRef57402 \">table 2</a>). Specimens should not be immersed in saline solution or solutions other than Michel's or Zeus medium.</p><p>The classical DIF findings in bullous pemphigoid and MMP include [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/39,69,70\" class=\"abstract_t\">39,69,70</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bullous pemphigoid </strong>&ndash;<strong> </strong>Linear immunoglobulin G (IgG) <span class=\"nowrap\">and/or</span> linear C3 staining along the basement membrane zone is present in greater than 90 percent of cases (<a href=\"image.htm?imageKey=DERM%2F86372%7EDERM%2F86950\" class=\"graphic graphic_picture graphicRef86372 graphicRef86950 \">picture 12A-B</a>); less intense linear basement membrane zone staining for IgM, IgA, <span class=\"nowrap\">and/or</span> IgE may be present.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mucous membrane pemphigoid </strong>&ndash; Linear IgG <span class=\"nowrap\">and/or</span> linear IgA <span class=\"nowrap\">and/or</span> linear C3 staining along the basement membrane zone is detected in approximately 80 to 100 percent of cases; linear IgE basement membrane zone staining can be detected in specimens from some patients.</p><p/><p>A modified DIF technique has been described utilizing basement membrane zone-split perilesional skin or mucosa from patients with suspected pemphigoid. Ideally, this allows for more precise localization of antibody binding within the epithelial basement membrane zone of diseased tissue and, therefore, additional information for diagnosis. However, the technique is infrequently utilized with DIF because of its technical difficulty. In particular, basement membrane zone separation often is difficult with inflamed skin and frequently is impossible to perform on mucosal specimens. Performing IIF with the patient's serum on basement membrane zone-split skin substrate is a more practical test. The diagnostic value of IIF is reviewed below. (See <a href=\"#H53290540\" class=\"local\">'Indirect immunofluorescence of serum'</a> below.)</p><p>Additional clues for diagnosis may be provided by analysis of the linear pattern of basement membrane zone antibody staining detected in DIF. Whereas an n-serrated pattern has been associated with bullous pemphigoid, MMP, anti-p200 pemphigoid, and linear IgA dermatosis (<a href=\"image.htm?imageKey=DERM%2F86951\" class=\"graphic graphic_picture graphicRef86951 \">picture 13</a>), a u-serrated pattern has been described in epidermolysis bullosa acquisita and bullous systemic lupus erythematosus (<a href=\"image.htm?imageKey=DERM%2F86952\" class=\"graphic graphic_picture graphicRef86952 \">picture 14</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/71,72\" class=\"abstract_t\">71,72</a>]. A true linear pattern is commonly observed along with the characteristic n-serrated and u-serrated patterns in all of these immunobullous diseases [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/71,72\" class=\"abstract_t\">71,72</a>].</p><p class=\"headingAnchor\" id=\"H53290540\"><span class=\"h3\">Indirect immunofluorescence of serum</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Indirect immunofluorescence (IIF) testing is used to detect circulating basement membrane zone antibodies in patients with pemphigoid (<a href=\"image.htm?imageKey=DERM%2F82836\" class=\"graphic graphic_picture graphicRef82836 \">picture 15A</a>). To perform this test, the patient's serum is overlaid on an epithelial tissue substrate, incubated, and then stained for fluorescent detection of antibodies (<a href=\"image.htm?imageKey=DERM%2F57402\" class=\"graphic graphic_table graphicRef57402 \">table 2</a>). (See <a href=\"topic.htm?path=approach-to-the-patient-with-cutaneous-blisters#H4714372\" class=\"medical medical_review\">&quot;Approach to the patient with cutaneous blisters&quot;, section on 'Indirect immunofluorescence'</a>.)</p><p class=\"headingAnchor\" id=\"H4989279\"><span class=\"h4\">Bullous pemphigoid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Various tissue substrates containing epithelial basement membrane zones have been used to perform IIF in bullous pemphigoid. Monkey esophagus is a useful substrate because it can broadly categorize immunobullous diseases based on antibody staining patterns (<a href=\"image.htm?imageKey=DERM%2F76558\" class=\"graphic graphic_algorithm graphicRef76558 \">algorithm 1</a>). (See <a href=\"topic.htm?path=paraneoplastic-pemphigus\" class=\"medical medical_review\">&quot;Paraneoplastic pemphigus&quot;</a> and <a href=\"topic.htm?path=linear-iga-bullous-dermatosis\" class=\"medical medical_review\">&quot;Linear IgA bullous dermatosis&quot;</a> and <a href=\"topic.htm?path=dermatitis-herpetiformis\" class=\"medical medical_review\">&quot;Dermatitis herpetiformis&quot;</a> and <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;</a>.)</p><p>Human skin (from cadavers or surgical waste) that is artificially split at the level of the lamina lucida (<strong>basement membrane zone-split skin</strong>) using prolonged (48 to 72 hours) exposure to 1 M sodium chloride (<strong>salt-split skin</strong>) or short (30 minutes) exposure to ethylenediaminetetraacetic acid (EDTA) is a useful substrate, particularly when basement membrane zone antibodies are known. This is because of the value of the test for distinguishing between certain subepithelial immunobullous diseases [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/67,73,74\" class=\"abstract_t\">67,73,74</a>]. </p><p>IIF with a basement membrane zone-split skin substrate aids in distinguishing between certain subepithelial immunobullous diseases because the test allows for localization of antibody deposition within the basement membrane zone. Specimens from patients with bullous pemphigoid typically demonstrate <strong>antibody deposition localized to the epidermal side of basement membrane zone-split skin</strong>, whereas in specimens from patients with epidermolysis bullosa acquisita, bullous lupus erythematosus, anti-laminin 332 pemphigoid, and anti-p200 pemphigoid, antibodies are typically found on the dermal side (<a href=\"image.htm?imageKey=DERM%2F82836%7EDERM%2F86374\" class=\"graphic graphic_picture graphicRef82836 graphicRef86374 \">picture 15A-B</a>). Combined epidermal-dermal staining patterns on basement membrane zone-split skin also are found in bullous pemphigoid and bullous lupus erythematosus (<a href=\"image.htm?imageKey=DERM%2F87135\" class=\"graphic graphic_picture graphicRef87135 \">picture 16</a>).</p><p>IIF is a highly specific test for bullous pemphigoid. In a retrospective study in which 313 patients with bullous pemphigoid were compared with 488 controls, the specificities of IIF on rabbit esophagus, IIF on monkey esophagus, and IIF on human salt-split skin for diagnosis were 96.5, 97.1, and 100 percent, respectively [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/66\" class=\"abstract_t\">66</a>]. The sensitivities of these tests for diagnosis were 73.2, 73.3, and 72 percent, respectively. DIF had a similar specificity, but was significantly more sensitive. The specificity of DIF was 98 percent and the sensitivity of DIF was 90.8 percent.</p><p class=\"headingAnchor\" id=\"H4989293\"><span class=\"h4\">Mucous membrane pemphigoid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In early studies of MMP, IIF was positive in fewer than one-third of patients [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/39\" class=\"abstract_t\">39</a>]. However, the use of human basement membrane zone-split skin <span class=\"nowrap\">and/or</span> concentrated serum may increase the likelihood of detecting circulating antibodies [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/39,73,75\" class=\"abstract_t\">39,73,75</a>]. In one series of eight patients with MMP, IIF on basement membrane zone-split skin was positive in 50 percent [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/73\" class=\"abstract_t\">73</a>]. A larger series of 67 patients found that IIF on a basement membrane zone-split skin substrate yielded positive antibodies in 84 percent of patients [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/75\" class=\"abstract_t\">75</a>].</p><p>In MMP, basement membrane zone split-skin IIF is particularly useful for recognizing patients at risk for malignancy-associated laminin 332 (previously known as laminin 5 and epiligrin) MMP; in this condition, antibodies are found along the dermal side of the split [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/76,77\" class=\"abstract_t\">76,77</a>]. Specific testing to confirm a diagnosis of anti-laminin 332 MMP remains limited to specialized centers and research settings [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/78\" class=\"abstract_t\">78</a>]. (See <a href=\"#H20007021\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H53290547\"><span class=\"h3\">Antigen-specific serologic testing</span></p><p class=\"headingAnchor\" id=\"H4989456\"><span class=\"h4\">Bullous pemphigoid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The identification of increased circulating IgG antibodies against bullous pemphigoid antigen 180 (BP180) and bullous pemphigoid antigen 230 (BP230) in patients with bullous pemphigoid has led to the use of adjunctive antigen-specific serologic testing for these basement membrane zone antigens in the diagnosis of this disorder. The most common technique used for this purpose is enzyme-linked immunosorbent assay (ELISA). (See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid#H589258\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid&quot;, section on 'Bullous pemphigoid'</a>.)</p><p>ELISAs for bullous pemphigoid antibodies are commercially available. This testing detects circulating IgG that reacts with BP180 (specifically, the NC16A domain of BP180, which is the most common antigenic target and which also has been known as bullous pemphigoid antigen 2 (BPAg2)) and with BP230 (specifically, fused antigenic targets from the N-terminal domain, central rod domain, and C-terminal domain of human BP230 and which also is known as bullous pemphigoid antigen 1 (BPAg1)). </p><p>ELISA for antibodies to the BP180 NC16A domain is useful for the diagnosis of bullous pemphigoid; studies have documented sensitivity and specificity of 72 to 90 percent and 90 to 99 percent, respectively [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/66,74,79,80\" class=\"abstract_t\">66,74,79,80</a>]. Since IgG BP180 NC16A antibody levels also correlate with disease activity [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/81\" class=\"abstract_t\">81</a>], many clinicians (including ourselves) utilize ELISA testing, not only to support the diagnosis of bullous pemphigoid, but also as a measure of the response to therapy.</p><p>ELISA for BP230 antibodies is less likely to be positive in bullous pemphigoid than ELISA testing for BP180 antibodies [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/66,74,82\" class=\"abstract_t\">66,74,82</a>]. In a retrospective study that evaluated ELISA results in 190 patients with bullous pemphigoid, the sensitivity and specificity of the assay for BP230 were 61 and 96 percent compared with 79 and 90 percent for BP180 [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/74\" class=\"abstract_t\">74</a>]. Moreover, combined testing for BP180 and BP230 antibodies was only slightly more sensitive than BP180 alone; the sensitivity and specificity of conjoint testing were 87 and 88 percent. Although this finding suggests that testing for BP230 should be reserved for patients who test negatively for BP180, immunodermatology laboratories, including ours, test for antibodies to both antigens in diagnostic panels for bullous pemphigoid [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/74\" class=\"abstract_t\">74</a>]. We have observed a subset of pemphigoid patients who have strong epidermal pattern basement membrane zone IgG antibodies by IIF and relatively high levels of IgG BP230 antibodies by ELISA, but normal IgG BP180 antibody levels. (See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid#H589251\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid&quot;, section on 'Pathogenesis'</a>.)</p><p>Also, in our experience, approximately 10 percent of patients with bullous pemphigoid demonstrate characteristic epidermal pattern IgG basement membrane zone antibodies by IIF and normal levels of both IgG BP180 and IgG BP230 antibodies by ELISA. These patients likely have antibodies to epitopes of BP180 or BP230 that are not recognized by commercial ELISA tests or may have antibodies to basement membrane zone antigens other than BP180 and BP230. In support of this observation, a study of 51 patients with clinical, histopathologic, and DIF findings consistent with bullous pemphigoid identified four patients (8 percent) in whom ELISA for BP180 NC16A was negative, three of whom also had negative ELISA for BP230 [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/83\" class=\"abstract_t\">83</a>]. Despite the negative ELISA for BP180, further analysis by immunoblot revealed strong reactivity to BP180 epitopes outside of NC16A in all four patients. These findings support the use of both IIF and ELISA to identify patients with bullous pemphigoid. In the study described, IIF on basement membrane zone-split skin was positive in three of the four ELISA BP180-negative patients. </p><p>The potential value of combining serologic studies also was demonstrated in a retrospective study of 313 patients with bullous pemphigoid and 488 controls that found that the sensitivity of a panel of serologic tests (IIF on rabbit esophagus, IIF on monkey esophagus, IIF on human salt-split skin, BP180 ELISA, and BP230 ELISA) for the diagnosis of bullous pemphigoid was 88.8 percent, a figure that closely approximated the sensitivity of DIF (90.8 percent) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/66\" class=\"abstract_t\">66</a>]. There was very high correlation between the results obtained with IIF on rabbit esophagus and IIF on monkey esophagus, suggesting that a similar sensitivity would have been obtained upon elimination of one of these tests. Lower sensitivities (59 to 76 percent) were detected for the individual serologic tests.</p><p>Of note, the detection of BP180 <span class=\"nowrap\">and/or</span> BP230 antibodies in serum does not definitively confirm a diagnosis of bullous pemphigoid. In one series of 337 people without bullous pemphigoid, 25 (7 percent) tested positively for one or both autoantibodies via ELISA [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/84\" class=\"abstract_t\">84</a>]. Correlation of ELISA findings with DIF will reduce the risk for misdiagnosis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/2\" class=\"abstract_t\">2</a>]. </p><p>Other techniques that have been utilized for the detection of antibodies in bullous pemphigoid include immunoblotting and immunoprecipitation. However, these tests are technically demanding and generally are not utilized in the clinical setting [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/2,67\" class=\"abstract_t\">2,67</a>].</p><p class=\"headingAnchor\" id=\"H4989441\"><span class=\"h4\">Mucous membrane pemphigoid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MMP may present with autoantibodies directed against a variety of antigens, including BP180, BP230, laminin 332 (previously known as epiligrin and laminin 5), alpha6beta4 integrin, and type VII collagen [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/37,60,85-88\" class=\"abstract_t\">37,60,85-88</a>]. However, limited sensitivity of ELISA testing for the diagnosis of MMP prevents the sole use of such testing. Pooled data analysis in a systematic review of studies reporting autoantibody profiles of patients with MMP who had positive immunoblot or immunoprecipitation to NC16a- found the sensitivity and specificity of ELISA using both NC16a and C-terminal epitope portions of BP180 to be 73 and 94 percent, respectively [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/88\" class=\"abstract_t\">88</a>]. Among patients with IgG reactivity against the C-terminal domain of BP180, the sensitivity and specificity of ELISA testing were 43 and 56 percent, respectively. </p><p>Antigen specific testing of serum for basement membrane zone antibodies other than BP180 and BP230 primarily is performed in research laboratories, limiting the value of this testing mode in the MMP population. However, additional tests may be available in the future. Further study is necessary to clarify whether the detection of salivary IgA and IgG antibodies to BP180 NC16A by ELISA is a useful diagnostic biomarker for MMP [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/89\" class=\"abstract_t\">89</a>]. (See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid#H589279\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid&quot;, section on 'Mucous membrane pemphigoid'</a>.)</p><p class=\"headingAnchor\" id=\"H588056\"><span class=\"h3\">Other laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Peripheral blood eosinophilia is common in patients with bullous pemphigoid, but is not a diagnostic finding [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/90,91\" class=\"abstract_t\">90,91</a>]. Increased serum IgE levels also are commonly found [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/92\" class=\"abstract_t\">92</a>].</p><p class=\"headingAnchor\" id=\"H20007021\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical findings in bullous pemphigoid and MMP may resemble a variety of other diseases, including other variants of pemphigoid and additional blistering or non-blistering diseases (<a href=\"image.htm?imageKey=DERM%2F69192\" class=\"graphic graphic_table graphicRef69192 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H12467777\"><span class=\"h2\">Other pemphigoid variants</span></p><p class=\"headingAnchor\" id=\"H12467836\"><span class=\"h3\">Pemphigoid gestationis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pemphigoid gestationis is an autoimmune subepidermal blistering disorder that develops during pregnancy and the postpartum period. Patients typically develop intensely pruritic papules, urticarial plaques, vesicles, and bullae that begin on the abdomen prior to spreading to other areas [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/93,94\" class=\"abstract_t\">93,94</a>]. The face and mucous membranes are usually spared. </p><p>Like bullous pemphigoid, patients with pemphigoid gestationis have circulating BP180 antibodies that are detected by enzyme linked immunosorbent assay (ELISA) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/95\" class=\"abstract_t\">95</a>]. On direct immunofluorescence (DIF), complement deposition predominates at the basement membrane zone. Pemphigoid gestationis is discussed in greater detail elsewhere. (See <a href=\"topic.htm?path=dermatoses-of-pregnancy#H2\" class=\"medical medical_review\">&quot;Dermatoses of pregnancy&quot;, section on 'Pemphigoid gestationis'</a>.)</p><p class=\"headingAnchor\" id=\"H12467889\"><span class=\"h3\">Anti-p200 (laminin gamma-1) pemphigoid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anti-p200 pemphigoid, also known as anti-laminin gamma-1 pemphigoid, is a variant of pemphigoid that is characterized by antibodies to a 200 kilodalton component of the dermal-epidermal junction. Indirect immunofluorescence (IIF) on basement membrane zone-split skin demonstrates dermal localization of basement membrane zone antibodies [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/96\" class=\"abstract_t\">96</a>] (see <a href=\"#H53290540\" class=\"local\">'Indirect immunofluorescence of serum'</a> above). The antigenic target in most cases is the gamma-1 subunit of laminin 311 (previously known as laminin 6).</p><p>Patients with this type of pemphigoid are usually younger than those with bullous pemphigoid, but present with similar clinical features. In one series of 29 patients with this disorder, 25 patients were male, and the mean age of patients was 61 years [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/97\" class=\"abstract_t\">97</a>]. Additionally, 14 patients had coexistent psoriasis. In another series of 12 patients, tense acral blisters and mucosal involvement were characteristic clinical features along with pruritus, and none had psoriasis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/98\" class=\"abstract_t\">98</a>]. </p><p>Specific testing to confirm the presence of antibodies to p200, or particularly to laminin gamma-1, remains limited to specialized centers and research settings [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/99\" class=\"abstract_t\">99</a>]. As a result, it is likely that patients with this form of pemphigoid are diagnosed erroneously with bullous pemphigoid or epidermolysis bullosa acquisita based on DIF findings [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/98\" class=\"abstract_t\">98</a>]. Anti-p200 pemphigoid is one of the few diagnoses indicated by IIF testing that detects serum immunoglobulin G (IgG) basement membrane zone antibodies binding to the dermal side of split skin substrate, also including epidermolysis bullosa acquisita, bullous lupus, and anti-laminin 332 pemphigoid. Techniques that have been used to specifically identify p200 antibodies include immunoblot with human dermal extract or ELISA to laminin gamma-1 as well as IIF on skin substrates deficient in type VII collagen and laminin 332 [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/98\" class=\"abstract_t\">98</a>].</p><p class=\"headingAnchor\" id=\"H12467264\"><span class=\"h3\">Brunsting-Perry pemphigoid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Brunsting-Perry pemphigoid is a cicatricial (scarring) form of pemphigoid that most commonly occurs in older men. Affected patients develop subepidermal blisters localized to the head or neck (<a href=\"image.htm?imageKey=DERM%2F54769\" class=\"graphic graphic_picture graphicRef54769 \">picture 17</a>). A variety of basement membrane zone antibodies have been detected in this variant [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/100-102\" class=\"abstract_t\">100-102</a>]. </p><p class=\"headingAnchor\" id=\"H12467920\"><span class=\"h2\">Other disorders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Examples of non-pemphigoid disorders in the differential diagnosis for patients with cutaneous lesions are included below (<a href=\"image.htm?imageKey=DERM%2F69192\" class=\"graphic graphic_table graphicRef69192 \">table 1</a> and <a href=\"image.htm?imageKey=DERM%2F76558\" class=\"graphic graphic_algorithm graphicRef76558 \">algorithm 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Urticaria and eczematous dermatitis </strong>&ndash; The prodromal phase lesions of bullous pemphigoid may resemble the erythematous and edematous plaques of urticaria or the erythematous papules or plaques of eczematous dermatitis. Unlike true urticaria, the lesions of bullous pemphigoid are not transient. DIF studies of biopsy specimens are useful for distinguishing both of these disorders from bullous pemphigoid. (See <a href=\"topic.htm?path=new-onset-urticaria\" class=\"medical medical_review\">&quot;New-onset urticaria&quot;</a> and <a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Skin-predominant epidermolysis bullosa acquisita </strong>&ndash;<strong> </strong>Epidermolysis bullosa acquisita is a rare disorder characterized by subepidermal blister formation involving the skin and mucous membranes (<a href=\"image.htm?imageKey=DERM%2F62505\" class=\"graphic graphic_picture graphicRef62505 \">picture 18</a>). Unlike bullous pemphigoid, immunofluorescence on basement membrane zone-split skin demonstrates antibody bound to the dermal side of the split, and residual scarring and milia are common. Specific ELISA testing for antibodies to type VII collagen is useful for making this diagnosis. (See <a href=\"topic.htm?path=epidermolysis-bullosa-acquisita\" class=\"medical medical_review\">&quot;Epidermolysis bullosa acquisita&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pemphigus </strong>&ndash;<strong> </strong>Pemphigus is a group of autoimmune blistering disorders characterized by autoantibodies directed against epithelial cell surface antigens (also known as intercellular substance antigens). The flaccid nature of blisters in pemphigus contrasts with the tense, subepidermal bullae in pemphigoid (<a href=\"image.htm?imageKey=DERM%2F53425%7EDERM%2F63170\" class=\"graphic graphic_picture graphicRef53425 graphicRef63170 \">picture 3A-B</a>). DIF studies are essential for diagnosis. Several pemphigus variants exist, including paraneoplastic pemphigus, which may show basement membrane zone antibodies in addition to cell surface antibodies. (See <a href=\"topic.htm?path=paraneoplastic-pemphigus\" class=\"medical medical_review\">&quot;Paraneoplastic pemphigus&quot;</a> and <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Linear IgA bullous dermatosis </strong>&ndash;<strong> </strong>Linear IgA bullous dermatosis is an autoimmune subepithelial blistering disorder that usually presents with annular and grouped tense vesicles arising on inflamed skin (<a href=\"image.htm?imageKey=DERM%2F56434\" class=\"graphic graphic_picture graphicRef56434 \">picture 19</a>). The skin lesions often are described as resembling a cluster of jewels. Mucosal sites also may be affected. The DIF finding of linear IgA antibody staining at the basement membrane zone in a perilesional skin biopsy specimen is essential for this diagnosis. (See <a href=\"topic.htm?path=linear-iga-bullous-dermatosis\" class=\"medical medical_review\">&quot;Linear IgA bullous dermatosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dermatitis herpetiformis </strong>&ndash;<strong> </strong>Intensely pruritic inflammatory papules, vesicles, or crusts with a predilection for the elbows, knees, and buttocks are characteristic of dermatitis herpetiformis, another autoimmune subepidermal blistering disorder (<a href=\"image.htm?imageKey=DERM%2F78315\" class=\"graphic graphic_picture graphicRef78315 \">picture 20</a>). The histopathologic finding of neutrophilic microabscesses in dermal papillary tips by H&amp;E and the immunohistopathologic detection of granular <span class=\"nowrap\">and/or</span> fibrillar IgA deposits in the papillary dermis by DIF are consistent with this diagnosis. (See <a href=\"topic.htm?path=dermatitis-herpetiformis\" class=\"medical medical_review\">&quot;Dermatitis herpetiformis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bullous lupus erythematosus </strong>&ndash;<strong> </strong>Bullous systemic lupus erythematosus is a rare disorder. The development of subepidermal blisters with neutrophilic infiltrates in a patient with systemic lupus erythematosus suggests this disease. (See <a href=\"topic.htm?path=overview-of-cutaneous-lupus-erythematosus#H538180729\" class=\"medical medical_review\">&quot;Overview of cutaneous lupus erythematosus&quot;, section on 'Bullous cutaneous lupus erythematosus'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H588016\"><span class=\"h2\">Mucosal lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other causes of mucosal erosions that must be distinguished from those associated with MMP and bullous pemphigoid include pemphigus variants (<a href=\"image.htm?imageKey=DERM%2F57924%7EDERM%2F59594\" class=\"graphic graphic_picture graphicRef57924 graphicRef59594 \">picture 21A-B</a>), linear IgA bullous dermatosis or epidermolysis bullosa acquisita with mucosal involvement, oral and genital mucosal lichen planus (<a href=\"image.htm?imageKey=DERM%2F54143%7EOBGYN%2F60224\" class=\"graphic graphic_picture graphicRef54143 graphicRef60224 \">picture 22A-B</a>), erythema multiforme (<a href=\"image.htm?imageKey=DERM%2F68153%7EDERM%2F58969\" class=\"graphic graphic_picture graphicRef68153 graphicRef58969 \">picture 23A-B</a>), Stevens-Johnson syndrome (<a href=\"image.htm?imageKey=EM%2F73805\" class=\"graphic graphic_picture graphicRef73805 \">picture 24</a>), HIV-associated mucosal lesions, Beh&ccedil;et syndrome, and aphthous ulcers (<a href=\"image.htm?imageKey=DERM%2F63475\" class=\"graphic graphic_picture graphicRef63475 \">picture 25</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/37\" class=\"abstract_t\">37</a>]. (See <a href=\"topic.htm?path=paraneoplastic-pemphigus\" class=\"medical medical_review\">&quot;Paraneoplastic pemphigus&quot;</a> and <a href=\"topic.htm?path=linear-iga-bullous-dermatosis\" class=\"medical medical_review\">&quot;Linear IgA bullous dermatosis&quot;</a> and <a href=\"topic.htm?path=epidermolysis-bullosa-acquisita\" class=\"medical medical_review\">&quot;Epidermolysis bullosa acquisita&quot;</a> and <a href=\"topic.htm?path=oral-lichen-planus-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Oral lichen planus: Pathogenesis, clinical features, and diagnosis&quot;</a> and <a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-erythema-multiforme\" class=\"medical medical_review\">&quot;Pathogenesis, clinical features, and diagnosis of erythema multiforme&quot;</a> and <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-behcet-syndrome\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Beh&ccedil;et syndrome&quot;</a> and <a href=\"topic.htm?path=oral-lesions#H16\" class=\"medical medical_review\">&quot;Oral lesions&quot;, section on 'Aphthous ulcerations'</a> and <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;</a>.)</p><p>The differential diagnosis for ocular involvement is reviewed separately. (See <a href=\"topic.htm?path=ocular-cicatricial-pemphigoid#H378908\" class=\"medical medical_review\">&quot;Ocular cicatricial pemphigoid&quot;, section on 'Differential diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H785956\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bullous pemphigoid and mucous membrane pemphigoid (MMP) are uncommon autoimmune subepithelial blistering disorders that affect skin and mucous membranes. (See <a href=\"#H784094\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Features of bullous pemphigoid</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The onset of blistering lesions in bullous pemphigoid is frequently preceded by a prodromal phase characterized by pruritic inflammatory plaques that resemble eczematous dermatitis or urticaria. Once the bullous phase develops, patients exhibit multiple tense 1 to 3 cm bullae as well as erosions and crusts at sites of ruptured bullae (<a href=\"image.htm?imageKey=DERM%2F54541%7EDERM%2F70352%7EDERM%2F79112\" class=\"graphic graphic_picture graphicRef54541 graphicRef70352 graphicRef79112 \">picture 2A-C</a>). The lesions of bullous pemphigoid usually heal without scarring. (See <a href=\"#H53290498\" class=\"local\">'Bullous pemphigoid'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The trunk and extremities are typically involved in bullous pemphigoid; localized presentations also may occur. Mucosal disease is present in 10 to 30 percent of patients. (See <a href=\"#H53290498\" class=\"local\">'Bullous pemphigoid'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Features of MMP</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>MMP most commonly presents as desquamative gingivitis or erosions of the oral mucosa. Other potential sites of mucosal involvement include the ocular conjunctiva, skin, pharynx, genitalia, nasal mucosa, larynx, anus, and esophagus (<a href=\"image.htm?imageKey=DERM%2F73874%7EDERM%2F52208%7EDERM%2F63997\" class=\"graphic graphic_picture graphicRef73874 graphicRef52208 graphicRef63997 \">picture 8A-C</a>). (See <a href=\"#H53290512\" class=\"local\">'Mucous membrane pemphigoid'</a> above and <a href=\"topic.htm?path=ocular-cicatricial-pemphigoid#H2913497\" class=\"medical medical_review\">&quot;Ocular cicatricial pemphigoid&quot;, section on 'Clinical manifestations'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Unlike bullous pemphigoid, lesions of MMP tend to scar. Scarring may result in serious functional impairment. (See <a href=\"#H53290512\" class=\"local\">'Mucous membrane pemphigoid'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients with the anti-laminin 332 (previously known as anti-laminin 5 or anti-epiligrin) form of MMP have an increased risk for internal malignancy. An evaluation for associated malignancy should be performed in patients with immunohistopathologic findings that suggest this disorder. Specific testing for antibodies against laminin 332 is not yet widely available. (See <a href=\"#H3867571\" class=\"local\">'Malignancy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Diagnosis</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The evaluation of patients with clinical findings suggestive of bullous pemphigoid or MMP begins with obtaining skin or mucous membrane biopsy specimens from both lesional tissue for H&amp;E (light microscopic histopathology) and perilesional tissue for direct immunofluorescence (DIF) (<a href=\"image.htm?imageKey=DERM%2F76558\" class=\"graphic graphic_algorithm graphicRef76558 \">algorithm 1</a>). DIF is the gold standard for diagnosis and demonstrates characteristic basement membrane zone antibody localization in almost all patients with bullous pemphigoid and the majority of patients with MMP (<a href=\"image.htm?imageKey=DERM%2F86372%7EDERM%2F86950\" class=\"graphic graphic_picture graphicRef86372 graphicRef86950 \">picture 12A-B</a>). (See <a href=\"#H554282\" class=\"local\">'Skin biopsy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Serologic studies to detect circulating basement membrane zone antibodies by indirect immunofluorescence (IIF) and enzyme-linked immunoassay (ELISA) also are useful for the diagnosis of bullous pemphigoid. Both DIF and serologic studies should be performed as part of the diagnostic evaluation (<a href=\"image.htm?imageKey=DERM%2F82836\" class=\"graphic graphic_picture graphicRef82836 \">picture 15A</a> and <a href=\"image.htm?imageKey=DERM%2F76558\" class=\"graphic graphic_algorithm graphicRef76558 \">algorithm 1</a>). (See <a href=\"#H53290540\" class=\"local\">'Indirect immunofluorescence of serum'</a> above and <a href=\"#H53290547\" class=\"local\">'Antigen-specific serologic testing'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The differential diagnosis of bullous pemphigoid and MMP is broad (<a href=\"image.htm?imageKey=DERM%2F69192\" class=\"graphic graphic_table graphicRef69192 \">table 1</a>). The possibility of other pemphigoid disorders, other blistering disorders, and nonbullous diseases must be considered. (See <a href=\"#H20007021\" class=\"local\">'Differential diagnosis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/1\" class=\"nounderline abstract_t\">Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011; 9:844.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/2\" class=\"nounderline abstract_t\">Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011; 29:427.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/3\" class=\"nounderline abstract_t\">Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity 2012; 45:55.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/4\" class=\"nounderline abstract_t\">Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol 2007; 23:257.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/5\" class=\"nounderline abstract_t\">Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev 2014; 13:477.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/6\" class=\"nounderline abstract_t\">Baum S, Sakka N, Artsi O, et al. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev 2014; 13:482.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/7\" class=\"nounderline abstract_t\">Uzun S, Durdu M. The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus. J Am Acad Dermatol 2006; 54:411.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/8\" class=\"nounderline abstract_t\">Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA 2000; 284:350.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/9\" class=\"nounderline abstract_t\">Benmously-Mlika R, Hammami-Ghorbel H, Mokhtar I. Onychomadesis during bullous pemphigoid. J Am Acad Dermatol 2013; 69:e306.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/10\" class=\"nounderline abstract_t\">Tosti A, Andr&eacute; M, Murrell DF. Nail involvement in autoimmune bullous disorders. Dermatol Clin 2011; 29:511.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/11\" class=\"nounderline abstract_t\">Tran JT, Mutasim DF. Localized bullous pemphigoid: a commonly delayed diagnosis. Int J Dermatol 2005; 44:942.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/12\" class=\"nounderline abstract_t\">Borradori L, Prost C, Wolkenstein P, et al. Localized pretibial pemphigoid and pemphigoid nodularis. J Am Acad Dermatol 1992; 27:863.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/13\" class=\"nounderline abstract_t\">Kitajima Y, Suzuki M, Johkura Y, Yaoita H. Localized bullous pemphigoid: report of a case with an immunofluorescence and electron microscopical studies on the lesional distribution of 180-KD bullous pemphigoid antigen, beta 4 integrin, and type VII collagen. J Dermatol 1993; 20:406.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/14\" class=\"nounderline abstract_t\">Kakurai M, Demitsu T, Azuma R, et al. Localized pemphigoid (pretibial type) with IgG antibody to BP180 NC16a domain successfully treated with minocycline and topical corticosteroid. Clin Exp Dermatol 2007; 32:759.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/15\" class=\"nounderline abstract_t\">Kohroh K, Suga Y, Mizuno Y, et al. Case of localized bullous pemphigoid with unique clinical manifestations in the lower legs. J Dermatol 2007; 34:482.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/16\" class=\"nounderline abstract_t\">Urano S. Localized bullous pemphigoid of the vulva. J Dermatol 1996; 23:580.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/17\" class=\"nounderline abstract_t\">Saad RW, Domloge-Hultsch N, Yancey KB, et al. Childhood localized vulvar pemphigoid is a true variant of bullous pemphigoid. Arch Dermatol 1992; 128:807.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/18\" class=\"nounderline abstract_t\">Batalla A, Pe&oacute;n G, De la Torre C. Localized bullous pemphigoid at urostomy site. Indian J Dermatol Venereol Leprol 2011; 77:625.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/19\" class=\"nounderline abstract_t\">Vande Maele DM, Reilly JC. Bullous pemphigoid at colostomy site: report of a case. Dis Colon Rectum 1997; 40:370.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/20\" class=\"nounderline abstract_t\">Sheerin N, Bourke JF, Holder J, et al. Bullous pemphigoid following radiotherapy. Clin Exp Dermatol 1995; 20:80.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/21\" class=\"nounderline abstract_t\">Mul VE, van Geest AJ, Pijls-Johannesma MC, et al. Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol 2007; 82:5.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/22\" class=\"nounderline abstract_t\">Quartey-Papafio CM, Hudson PM. Bullous pemphigoid initially localized to sites of burns (scalds) in a patient on sulphasalazine for ulcerative colitis. Clin Exp Dermatol 1994; 19:281.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/23\" class=\"nounderline abstract_t\">Macfarlane AW, Verbov JL. Trauma-induced bullous pemphigoid. Clin Exp Dermatol 1989; 14:245.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/24\" class=\"nounderline abstract_t\">Salomon RJ, Briggaman RA, Wernikoff SY, Kayne AL. Localized bullous pemphigoid. A mimic of acute contact dermatitis. Arch Dermatol 1987; 123:389.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/25\" class=\"nounderline abstract_t\">de la Fuente S, Hern&aacute;ndez-Mart&iacute;n &Aacute;, de Lucas R, et al. Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review. Pediatr Dermatol 2013; 30:741.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/26\" class=\"nounderline abstract_t\">Nguyen T, Kwan JM, Ahmed AR. Relationship between radiation therapy and bullous pemphigoid. Dermatology 2014; 229:88.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/27\" class=\"nounderline abstract_t\">Kaplan RP. Cutaneous involvement in localized forms of bullous pemphigoid. Clin Dermatol 1987; 5:43.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/28\" class=\"nounderline abstract_t\">Bakker CV, Terra JB, Pas HH, Jonkman MF. Bullous pemphigoid as pruritus in the elderly: a common presentation. JAMA Dermatol 2013; 149:950.</a></li><li class=\"breakAll\">Alonso-Llamazares J, Peters MS, Leiferman KM. Bullous Pemphigoid. In: Atlas of Bullous Disease, Jordon RE (Ed), Churchill Livingstone, San Francisco 2000. p.43.</li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/30\" class=\"nounderline abstract_t\">Zhang W, Liu Y, Li C. Generalised nodules in pemphigoid nodularis. Lancet 2017; 389:1930.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/31\" class=\"nounderline abstract_t\">Kim J, Chavel S, Girardi M, McNiff JM. Pemphigoid vegetans: a case report and review of the literature. J Cutan Pathol 2008; 35:1144.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/32\" class=\"nounderline abstract_t\">Chan LS, Dorman MA, Agha A, et al. Pemphigoid vegetans represents a bullous pemphigoid variant. Patient's IgG autoantibodies identify the major bullous pemphigoid antigen. J Am Acad Dermatol 1993; 28:331.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/33\" class=\"nounderline abstract_t\">Gharami RC, Kumar P, Mondal A, Ghosh K. Dyshidrosiform Pemphigus vulgaris: Report of an unusual case. Dermatol Online J 2010; 16:10.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/34\" class=\"nounderline abstract_t\">Kim YJ, Kim MY, Kim HO, Park YM. Dyshidrosiform bullous pemphigoid. Acta Derm Venereol 2004; 84:253.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/35\" class=\"nounderline abstract_t\">Lai FJ, Sheu HM, Lee JY, et al. Vesicular pemphigoid with circulating autoantibodies against 230-kDa and 180-kDa proteins, and additional autoantibodies against 97-kDa and 45-kDa proteins. Int J Dermatol 2007; 46:206.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/36\" class=\"nounderline abstract_t\">Zillikens D, Caux F, Mascaro JM, et al. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 1999; 113:117.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/37\" class=\"nounderline abstract_t\">Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/38\" class=\"nounderline abstract_t\">Ahmed AR, Hombal SM. Cicatricial pemphigoid. Int J Dermatol 1986; 25:90.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/39\" class=\"nounderline abstract_t\">Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43:571.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/40\" class=\"nounderline abstract_t\">Foureur N, Descamps V, Lebrun-Vignes B, et al. Bullous pemphigoid in a leg affected with hemiparesia: a possible relation of neurological diseases with bullous pemphigoid? Eur J Dermatol 2001; 11:230.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/41\" class=\"nounderline abstract_t\">Stinco G, Codutti R, Scarbolo M, et al. A retrospective epidemiological study on the association of bullous pemphigoid and neurological diseases. Acta Derm Venereol 2005; 85:136.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/42\" class=\"nounderline abstract_t\">Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011; 131:631.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/43\" class=\"nounderline abstract_t\">Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011; 131:637.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/44\" class=\"nounderline abstract_t\">Masouy&eacute; I, Schmied E, Didierjean L, et al. Bullous pemphigoid and multiple sclerosis: more than a coincidence? Report of three cases. J Am Acad Dermatol 1989; 21:63.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/45\" class=\"nounderline abstract_t\">Kirtschig G, Walkden VM, Venning VA, Wojnarowska F. Bullous pemphigoid and multiple sclerosis: a report of three cases and review of the literature. Clin Exp Dermatol 1995; 20:449.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/46\" class=\"nounderline abstract_t\">Stinco G, Mattighello P, Zanchi M, Patrone P. Multiple sclerosis and bullous pemphigoid: a casual association or a pathogenetic correlation? Eur J Dermatol 2002; 12:186.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/47\" class=\"nounderline abstract_t\">Nielsen NM, Frisch M, Rostgaard K, et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler 2008; 14:823.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/48\" class=\"nounderline abstract_t\">Chosidow O, Doppler V, Bensimon G, et al. Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease? Arch Dermatol 2000; 136:521.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/49\" class=\"nounderline abstract_t\">Gambichler T, Segert H, H&ouml;xtermann S, et al. Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations. J Eur Acad Dermatol Venereol 2015; 29:1758.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/50\" class=\"nounderline abstract_t\">Oh DD, Zhao CY, Murrell DF. A review of case-control studies on the risk factors for the development of autoimmune blistering diseases. J Eur Acad Dermatol Venereol 2016; 30:595.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/51\" class=\"nounderline abstract_t\">Ren Z, Hsu DY, Brieva J, et al. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. Br J Dermatol 2017; 176:87.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/52\" class=\"nounderline abstract_t\">Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler 2010; 16:855.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/53\" class=\"nounderline abstract_t\">Bouras C, Riederer BM, K&ouml;vari E, et al. Humoral immunity in brain aging and Alzheimer's disease. Brain Res Brain Res Rev 2005; 48:477.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/54\" class=\"nounderline abstract_t\">Laffitte E, Burkhard PR, Fontao L, et al. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis? Br J Dermatol 2005; 152:537.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/55\" class=\"nounderline abstract_t\">Chen J, Li L, Chen J, et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology 2011; 57:211.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/56\" class=\"nounderline abstract_t\">Li L, Chen J, Wang B, et al. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160:1343.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/57\" class=\"nounderline abstract_t\">Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357:1850.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/58\" class=\"nounderline abstract_t\">Sadler E, Lazarova Z, Sarasombath P, Yancey KB. A widening perspective regarding the relationship between anti-epiligrin cicatricial pemphigoid and cancer. J Dermatol Sci 2007; 47:1.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/59\" class=\"nounderline abstract_t\">Miyazaki K. Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion. Cancer Sci 2006; 97:91.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/60\" class=\"nounderline abstract_t\">Bernard P, Antonicelli F, Bedane C, et al. Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid. JAMA Dermatol 2013; 149:533.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/61\" class=\"nounderline abstract_t\">Ruocco E, Wolf R, Caccavale S, et al. Bullous pemphigoid: associations and management guidelines: facts and controversies. Clin Dermatol 2013; 31:400.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/62\" class=\"nounderline abstract_t\">Cai SC, Allen JC, Lim YL, et al. Association of Bullous Pemphigoid and Malignant Neoplasms. JAMA Dermatol 2015; 151:665.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/63\" class=\"nounderline abstract_t\">Ong E, Goldacre R, Hoang U, et al. Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999-2011. Arch Dermatol Res 2014; 306:75.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/64\" class=\"nounderline abstract_t\">Lara-Corrales I, Pope E. Autoimmune blistering diseases in children. Semin Cutan Med Surg 2010; 29:85.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/65\" class=\"nounderline abstract_t\">Fisler RE, Saeb M, Liang MG, et al. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol 2003; 25:183.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/66\" class=\"nounderline abstract_t\">S&aacute;rdy M, Kostaki D, Varga R, et al. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. J Am Acad Dermatol 2013; 69:748.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/67\" class=\"nounderline abstract_t\">Chan YC, Sun YJ, Ng PP, Tan SH. Comparison of immunofluorescence microscopy, immunoblotting and enzyme-linked immunosorbent assay methods in the laboratory diagnosis of bullous pemphigoid. Clin Exp Dermatol 2003; 28:651.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/68\" class=\"nounderline abstract_t\">Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010; 10:84.</a></li><li class=\"breakAll\">Weedon D. The vesicobullous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier, Edinburgh 2010. p.123.</li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/70\" class=\"nounderline abstract_t\">Yayli S, Pelivani N, Beltraminelli H, et al. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis. Br J Dermatol 2011; 165:1133.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/71\" class=\"nounderline abstract_t\">Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 2004; 151:112.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/72\" class=\"nounderline abstract_t\">Terra JB, Pas HH, Hertl M, et al. Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin-332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 Dutch patients. Br J Dermatol 2011; 165:815.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/73\" class=\"nounderline abstract_t\">Kelly SE, Wojnarowska F. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol 1988; 118:31.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/74\" class=\"nounderline abstract_t\">Roussel A, Benichou J, Randriamanantany ZA, et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011; 147:293.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/75\" class=\"nounderline abstract_t\">Setterfield J, Shirlaw PJ, Kerr-Muir M, et al. Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. Br J Dermatol 1998; 138:602.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/76\" class=\"nounderline abstract_t\">Domloge-Hultsch N, Anhalt GJ, Gammon WR, et al. Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder. Arch Dermatol 1994; 130:1521.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/77\" class=\"nounderline abstract_t\">Domloge-Hultsch N, Gammon WR, Briggaman RA, et al. Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 1992; 90:1628.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/78\" class=\"nounderline abstract_t\">Bekou V, Thoma-Uszynski S, Wendler O, et al. Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA. J Invest Dermatol 2005; 124:732.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/79\" class=\"nounderline abstract_t\">Sitaru C, D&auml;hnrich C, Probst C, et al. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16:770.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/80\" class=\"nounderline abstract_t\">Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002; 30:224.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/81\" class=\"nounderline abstract_t\">Schmidt E, Obe K, Br&ouml;cker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136:174.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/82\" class=\"nounderline abstract_t\">Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011; 147:286.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/83\" class=\"nounderline abstract_t\">Fairley JA, Bream M, Fullenkamp C, et al. Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay. J Am Acad Dermatol 2013; 68:395.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/84\" class=\"nounderline abstract_t\">Wieland CN, Comfere NI, Gibson LE, et al. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol 2010; 146:21.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/85\" class=\"nounderline abstract_t\">Rashid KA, G&uuml;rcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol 2006; 126:2631.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/86\" class=\"nounderline abstract_t\">Chan LS, Majmudar AA, Tran HH, et al. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 1997; 108:848.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/87\" class=\"nounderline abstract_t\">Lazarova Z, Yee C, Lazar J, Yancey KB. IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit. Clin Immunol 2001; 101:100.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/88\" class=\"nounderline abstract_t\">Amber KT, Bloom R, Hertl M. A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti-laminin-332 IgG with oropharyngeal involvement and the usefulness of ELISA. J Eur Acad Dermatol Venereol 2016; 30:72.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/89\" class=\"nounderline abstract_t\">Ali S, Kelly C, Challacombe SJ, et al. Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid. Br J Dermatol 2016; 174:1022.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/90\" class=\"nounderline abstract_t\">Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Prevalence and clinical features of Thai patients with bullous pemphigoid. Asian Pac J Allergy Immunol 2011; 29:66.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/91\" class=\"nounderline abstract_t\">Bushkell LL, Jordon RE. Bullous pemphigoid: a cause of peripheral blood eosinophilia. J Am Acad Dermatol 1983; 8:648.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/92\" class=\"nounderline abstract_t\">Arbesman CE, Wypych JI, Reisman RE, Beutner EH. IgE levels in sera of patients with pemphigus or bullous pemphigoid. Arch Dermatol 1974; 110:378.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/93\" class=\"nounderline abstract_t\">Ambros-Rudolph CM, Black MM. From prurigo gestationis Besnier to atopic eruption of pregnancy: the confusing nosology of the less well-defined dermatoses of pregnancy has been largely clarified. Clin Dermatol 2006; 24:545.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/94\" class=\"nounderline abstract_t\">Ambros-Rudolph CM, M&uuml;llegger RR, Vaughan-Jones SA, et al. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006; 54:395.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/95\" class=\"nounderline abstract_t\">Giudice GJ, Wilske KC, Anhalt GJ, et al. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol 1994; 102:878.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/96\" class=\"nounderline abstract_t\">Zillikens D, Kawahara Y, Ishiko A, et al. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996; 106:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/97\" class=\"nounderline abstract_t\">Dilling A, Rose C, Hashimoto T, et al. Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease. J Dermatol 2007; 34:1.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/98\" class=\"nounderline abstract_t\">Meijer JM, Diercks GF, Schmidt E, et al. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid. JAMA Dermatol 2016; 152:897.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/99\" class=\"nounderline abstract_t\">Groth S, Recke A, Vafia K, et al. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol 2011; 164:76.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/100\" class=\"nounderline abstract_t\">Mart&iacute;n JM, Pinazo I, Molina I, et al. Cicatricial pemphigoid of the Brunsting-Perry type. Int J Dermatol 2009; 48:293.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/101\" class=\"nounderline abstract_t\">Jedlickova H, Niedermeier A, Zga&#382;arov&aacute; S, Hertl M. Brunsting-Perry pemphigoid of the scalp with antibodies against laminin 332. Dermatology 2011; 222:193.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid/abstract/102\" class=\"nounderline abstract_t\">Fukuda S, Tsuruta D, Uchiyama M, et al. Brunsting-Perry type pemphigoid with IgG autoantibodies to laminin-332, BP230 and desmoplakins I/II. Br J Dermatol 2011; 165:433.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 16176 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H785956\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H590249\" id=\"outline-link-H590249\">INTRODUCTION</a></li><li><a href=\"#H784094\" id=\"outline-link-H784094\">CLINICAL FEATURES</a><ul><li><a href=\"#H53290498\" id=\"outline-link-H53290498\">Bullous pemphigoid</a></li><li><a href=\"#H53290512\" id=\"outline-link-H53290512\">Mucous membrane pemphigoid</a></li></ul></li><li><a href=\"#H3867557\" id=\"outline-link-H3867557\">ASSOCIATED DISORDERS</a><ul><li><a href=\"#H3867564\" id=\"outline-link-H3867564\">Neurologic disorders</a></li><li><a href=\"#H3867571\" id=\"outline-link-H3867571\">Malignancy</a></li></ul></li><li><a href=\"#H785112\" id=\"outline-link-H785112\">DISEASE COURSE</a></li><li><a href=\"#H20007006\" id=\"outline-link-H20007006\">DIAGNOSIS</a><ul><li><a href=\"#H587825\" id=\"outline-link-H587825\">Clinical assessment</a></li><li><a href=\"#H20007014\" id=\"outline-link-H20007014\">Laboratory tests</a><ul><li><a href=\"#H404213\" id=\"outline-link-H404213\">- Our approach</a></li><li><a href=\"#H554282\" id=\"outline-link-H554282\">- Skin biopsy</a><ul><li><a href=\"#H4988524\" id=\"outline-link-H4988524\">Light microscopy of formalin-fixed tissue</a></li><li><a href=\"#H53290533\" id=\"outline-link-H53290533\">Direct immunofluorescence</a></li></ul></li><li><a href=\"#H53290540\" id=\"outline-link-H53290540\">- Indirect immunofluorescence of serum</a><ul><li><a href=\"#H4989279\" id=\"outline-link-H4989279\">Bullous pemphigoid</a></li><li><a href=\"#H4989293\" id=\"outline-link-H4989293\">Mucous membrane pemphigoid</a></li></ul></li><li><a href=\"#H53290547\" id=\"outline-link-H53290547\">- Antigen-specific serologic testing</a><ul><li><a href=\"#H4989456\" id=\"outline-link-H4989456\">Bullous pemphigoid</a></li><li><a href=\"#H4989441\" id=\"outline-link-H4989441\">Mucous membrane pemphigoid</a></li></ul></li><li><a href=\"#H588056\" id=\"outline-link-H588056\">- Other laboratory findings</a></li></ul></li></ul></li><li><a href=\"#H20007021\" id=\"outline-link-H20007021\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H12467777\" id=\"outline-link-H12467777\">Other pemphigoid variants</a><ul><li><a href=\"#H12467836\" id=\"outline-link-H12467836\">- Pemphigoid gestationis</a></li><li><a href=\"#H12467889\" id=\"outline-link-H12467889\">- Anti-p200 (laminin gamma-1) pemphigoid</a></li><li><a href=\"#H12467264\" id=\"outline-link-H12467264\">- Brunsting-Perry pemphigoid</a></li></ul></li><li><a href=\"#H12467920\" id=\"outline-link-H12467920\">Other disorders</a></li><li><a href=\"#H588016\" id=\"outline-link-H588016\">Mucosal lesions</a></li></ul></li><li><a href=\"#H785956\" id=\"outline-link-H785956\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/16176|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=DERM/76558\" class=\"graphic graphic_algorithm\">- Clinical testing for pemphigoid</a></li></ul></li><li><div id=\"DERM/16176|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/67891\" class=\"graphic graphic_figure\">- Epidermal basement membrane zone</a></li></ul></li><li><div id=\"DERM/16176|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/80385\" class=\"graphic graphic_picture\">- Bullous pemphigoid eczematous</a></li><li><a href=\"image.htm?imageKey=DERM/54541\" class=\"graphic graphic_picture\">- Bullous pemphigoid tense bullae</a></li><li><a href=\"image.htm?imageKey=DERM/70352\" class=\"graphic graphic_picture\">- Bullous pemphigoid tense bullae 2</a></li><li><a href=\"image.htm?imageKey=DERM/79112\" class=\"graphic graphic_picture\">- Bullous pemphigoid on urticarial plaque</a></li><li><a href=\"image.htm?imageKey=DERM/53425\" class=\"graphic graphic_picture\">- Pemphigus vulgaris bullae and erosions</a></li><li><a href=\"image.htm?imageKey=DERM/63170\" class=\"graphic graphic_picture\">- Pemphigus vulgaris large erosions</a></li><li><a href=\"image.htm?imageKey=DERM/72866\" class=\"graphic graphic_picture\">- Bullous pemphigoid multiple lesions</a></li><li><a href=\"image.htm?imageKey=DERM/78910\" class=\"graphic graphic_picture\">- Bullous pemphigoid axillae</a></li><li><a href=\"image.htm?imageKey=DERM/59590\" class=\"graphic graphic_picture\">- Bullous pemphigoid trunk</a></li><li><a href=\"image.htm?imageKey=DERM/66179\" class=\"graphic graphic_picture\">- Bullous pemphigoid oral mucosa</a></li><li><a href=\"image.htm?imageKey=DERM/71249\" class=\"graphic graphic_picture\">- Bullous pemphigoid on lower legs</a></li><li><a href=\"image.htm?imageKey=DERM/50357\" class=\"graphic graphic_picture\">- Dyshidrosiform bullous pemphigoid</a></li><li><a href=\"image.htm?imageKey=DERM/73874\" class=\"graphic graphic_picture\">- Mucous membrane pemphigoid gingivitis</a></li><li><a href=\"image.htm?imageKey=DERM/52208\" class=\"graphic graphic_picture\">- Mucous membrane pemphigoid lip</a></li><li><a href=\"image.htm?imageKey=DERM/63997\" class=\"graphic graphic_picture\">- Mucous membrane pemphigoid palate</a></li><li><a href=\"image.htm?imageKey=DERM/58359\" class=\"graphic graphic_picture\">- Bullous pemphigoid in childhood</a></li><li><a href=\"image.htm?imageKey=DERM/79687\" class=\"graphic graphic_picture\">- Bullous pemphigoid eosinophilic spongiosis</a></li><li><a href=\"image.htm?imageKey=PC/66267\" class=\"graphic graphic_picture\">- Bullous pemphigoid pathology</a></li><li><a href=\"image.htm?imageKey=DERM/86372\" class=\"graphic graphic_picture\">- Bullous pemphigoid direct immunofluorescence 400X</a></li><li><a href=\"image.htm?imageKey=DERM/86950\" class=\"graphic graphic_picture\">- Bullous pemphigoid direct immunofluorescence C3 deposits</a></li><li><a href=\"image.htm?imageKey=DERM/86951\" class=\"graphic graphic_picture\">- N-serrated pattern on direct immunofluorescence</a></li><li><a href=\"image.htm?imageKey=DERM/86952\" class=\"graphic graphic_picture\">- U-serrated pattern on direct immunofluorescence</a></li><li><a href=\"image.htm?imageKey=DERM/82836\" class=\"graphic graphic_picture\">- Bullous pemphigoid IIF</a></li><li><a href=\"image.htm?imageKey=DERM/86374\" class=\"graphic graphic_picture\">- Epidermolysis bullosa acquisita split skin immunofluorescence</a></li><li><a href=\"image.htm?imageKey=DERM/87135\" class=\"graphic graphic_picture\">- Indirect immunofluorescence on basement membrane zone-split skin</a></li><li><a href=\"image.htm?imageKey=DERM/54769\" class=\"graphic graphic_picture\">- Brunsting-Perry pemphigoid</a></li><li><a href=\"image.htm?imageKey=DERM/62505\" class=\"graphic graphic_picture\">- Epidermolysis bullosa acquisita</a></li><li><a href=\"image.htm?imageKey=DERM/56434\" class=\"graphic graphic_picture\">- Linear IgA bullous dermatosis</a></li><li><a href=\"image.htm?imageKey=DERM/78315\" class=\"graphic graphic_picture\">- Dermatitis herpetiformis elbows</a></li><li><a href=\"image.htm?imageKey=DERM/57924\" class=\"graphic graphic_picture\">- Pemphigus vulgaris - oral</a></li><li><a href=\"image.htm?imageKey=DERM/59594\" class=\"graphic graphic_picture\">- Paraneoplastic pemphigus oral findings</a></li><li><a href=\"image.htm?imageKey=DERM/54143\" class=\"graphic graphic_picture\">- Oral lichen planus - gingiva</a></li><li><a href=\"image.htm?imageKey=OBGYN/60224\" class=\"graphic graphic_picture\">- Erosive lichen planus</a></li><li><a href=\"image.htm?imageKey=DERM/68153\" class=\"graphic graphic_picture\">- Erythema multiforme lip</a></li><li><a href=\"image.htm?imageKey=DERM/58969\" class=\"graphic graphic_picture\">- Erythema multiforme tongue</a></li><li><a href=\"image.htm?imageKey=EM/73805\" class=\"graphic graphic_picture\">- Mucosal changes in Stevens-Johnson syndrome</a></li><li><a href=\"image.htm?imageKey=DERM/63475\" class=\"graphic graphic_picture\">- Aphthous ulcers</a></li></ul></li><li><div id=\"DERM/16176|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/69192\" class=\"graphic graphic_table\">- Differential diagnosis of pemphigoid</a></li><li><a href=\"image.htm?imageKey=DERM/57402\" class=\"graphic graphic_table\">- Diagnostic pemphigoid testing</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-cutaneous-blisters\" class=\"medical medical_review\">Approach to the patient with cutaneous blisters</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-behcet-syndrome\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Beh&ccedil;et syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermatitis-herpetiformis\" class=\"medical medical_review\">Dermatitis herpetiformis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermatoses-of-pregnancy\" class=\"medical medical_review\">Dermatoses of pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid\" class=\"medical medical_review\">Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidermolysis-bullosa-acquisita\" class=\"medical medical_review\">Epidermolysis bullosa acquisita</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=linear-iga-bullous-dermatosis\" class=\"medical medical_review\">Linear IgA bullous dermatosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-prognosis-of-bullous-pemphigoid\" class=\"medical medical_review\">Management and prognosis of bullous pemphigoid</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-mucous-membrane-pemphigoid\" class=\"medical medical_review\">Management of mucous membrane pemphigoid</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=new-onset-urticaria\" class=\"medical medical_review\">New-onset urticaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ocular-cicatricial-pemphigoid\" class=\"medical medical_review\">Ocular cicatricial pemphigoid</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oral-lesions\" class=\"medical medical_review\">Oral lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oral-lichen-planus-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Oral lichen planus: Pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-cutaneous-lupus-erythematosus\" class=\"medical medical_review\">Overview of cutaneous lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paraneoplastic-pemphigus\" class=\"medical medical_review\">Paraneoplastic pemphigus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-erythema-multiforme\" class=\"medical medical_review\">Pathogenesis, clinical features, and diagnosis of erythema multiforme</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of pemphigus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=skin-biopsy-techniques\" class=\"medical medical_review\">Skin biopsy techniques</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis</a></li></ul></div></div>","javascript":null}